Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to assess the chronic safety and performance of the Axone left ventricular (LV) micro-lead.
This is a interventional, pivotal, prospective, single arm, open label, multicenter, international trial.
The device under investigation is the Axone system, consisting of:
The primary endpoint data will be used to support CE marking of the Axone system.
The primary endpoints will be evaluated at 6 months post-implantation. Subjects will be followed-up at 6 weeks, 3 months, 6 months, 12 months post-implantation, then yearly until 4 years post-implantation.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Axone 4LV Lead | Experimental | Subjects implanted with the Axone 4LV Lead |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Implantation of the Axone 4LV Lead | Device | Implantation of the Axone 4LV Lead |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety co-primary endpoint, defined as Axone system related complication free rate at 6 months post implant | A complication is defined as any Serious Adverse Device Effect (SADE) resulting in death or requiring invasive intervention. Safety co-primary endpoint assessment will be based on independent event adjudication by a Clinical Event Committee (CEC). | 6 months |
| Performance co-primary endpoint, defined as LV pacing success rate at 6 months post implant | LV pacing success is defined as at least one LV pacing vector with:
| 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Bizone LV pacing success rate at 6 months post implant | Bizone LV pacing success is defined as two distant pacing vectors with:
| 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Axone 4LV implantation success rate | At implant, preferably within 15 days of enrollment | |
| Implantation duration | At implant, preferably within 15 days of enrollment | |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Frédéric Anselme, MD | CHU de Rouen, France | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kepler Universitätsklinikum | Linz | Austria | ||||
| CH Annecy Genevois |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27206819 | Background | Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20. No abstract available. | |
| 15753115 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Fluoroscopy time |
Fluoroscopy time is measured in minutes |
| At implant, preferably within 15 days of enrollment |
| Fluoroscopy dose | Fluoroscopy dose is measured using dose area product (Gray.cm^2) | At implant, preferably within 15 days of enrollment |
| Axone system handling assessment | Implanters will be asked to fill in a handling questionnaire and record observations related to the use of the Axone system. | At implant, preferably within 15 days of enrollment |
| Axone implanters' learning curve | This endpoint will be based on fluoroscopy time for implantation. The effect of removing the 1st, 2nd, 3rd, etc implanted subjects on mean fluoroscopy time (per implanter and per site) will be calculated. | At implant, preferably within 15 days of enrollment |
| Number of excitable myocardium areas at implant | "Excitable myocardium areas" are areas that can be paced by the implanted Axone 4LV lead. | At implant, preferably within 15 days of enrollment |
| Effect of CRT therapy, in particular bizone pacing, on QRS parameters, at discharge and 6 months post implant | The effect of monozone and bizone CRT pacing on duration of QRS is measured in milliseconds. | At discharge, within 7 days of implant, and at 6 months |
| Effect of CRT therapy, in particular bizone pacing, on Left Pre-Ejection Interval (LPEI), at discharge | LPEI (in milliseconds) is an electromechanical parameter that can be assessed using echocardiography. | At discharge, within 7 days of implant |
| Axone 4LV lead pacing threshold | Pacing threshold is measured in Volts. | Discharge (within 7 days of implant), 6 weeks, 3 months, 6 months, 12 months, 24 months 36 months, 48 months |
| Axone 4LV lead pacing impedance | Pacing impedance is measured in Ohms. | Discharge (within 7 days of implant), 6 weeks, 3 months, 6 months, 12 months, 24 months 36 months, 48 months |
| Presence of phrenic nerve stimulation (PNS) with the Axone 4LV lead | The presence of PNS will be assessed at 10V using an external pacing system analyzer at implant, or at pacing threshold +2V at other visits. | Implant (preferably within 15 days of enrollment), discharge (within 7 days of implant), 6 weeks, 3 months, 6 months |
| Axone 4LV lead programming | Lead programming will be reported using: (i) pacing amplitude (Volts), pulse width (milliseconds) and pacing vector(s) selected. | Discharge (within 7 days of implant), 6 weeks, 3 months, 6 months, 12 months, 24 months 36 months, 48 months |
| Energy consumption associated with Axone 4LV lead | Energy will be calculated using the formula: E=(pacing amplitude^2 x pulse width)/impedance. Energy, pacing amplitude, pulse width and impedance are measured in Joules, Volts, milliseconds, and Ohms, respectively. | 6 months |
| Axone system-related annual complication-free rate | Definition of Axone system related complication is the same as for primary safety endpoint. | 12 months, 24 months 36 months, 48 months |
| Clinical response to CRT at 12 months post implant | Clinical response will be determined by looking at functional improvement, reverse remodelling, freedom from heart failure events, and rate of non-responders: (i) functional improvement is defined as improvement in ≥1 NYHA (New York Heart Association) class from baseline to 12 months. (ii) reverse remodelling is a ≥12% increase in left ventricular end systolic volume index (LVESVi: LVESV [mL] and body surface area [m^2] will be combined to report LVESVi). (iii) freedom from heart failure events is defined as an absence of death or HF hospitalization. (iv) non-responders are all those who are not responders. A responder is defined as a subject that is not dead and who did not experience any HF hospitalization and that has a stable or improved NYHA class versus baseline. | 12 months |
| Annecy |
| France |
| CHRU Hopital Trousseau | Chambray-lès-Tours | France |
| CHU de Clermont-Ferrand | Clermont-Ferrand | France |
| CHU Grenoble | Grenoble | France |
| CHRU de Lille - Hôpital Cardiologique | Lille | France |
| CHU Pontchaillou | Rennes | France |
| CHU de Rouen | Rouen | France |
| CHU Toulouse | Toulouse | France |
| Universitätsklinikum Hamburg Eppendorf | Hamburg | Germany |
| Universitätsklinikum Heidelberg | Heidelberg | Germany |
| Universitätsklinikum Schleswig-Holstein Campus Kiel | Kiel | Germany |
| ASST Spedali Civili di Brescia | Brescia | Italy |
| Ospedale Pellegrini | Naples | Italy |
| Ospedale Policlinico Federico II | Naples | Italy |
| Isala Klinieken | Zwolle | Netherlands |
| Centro Hospitalar Universitário Lisboa Norte - Hospital de Santa Maria | Lisbon | Portugal |
| Centro Hospitalar Universitário do Porto | Porto | Portugal |
| Hospital Universitario General de Alicante | Alicante | Spain |
| Hospital Universitario La Fe | Valencia | Spain |
| Hospital Álvaro Cunqueiro | Vigo | Spain |
| Background |
| Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005 Apr 14;352(15):1539-49. doi: 10.1056/NEJMoa050496. Epub 2005 Mar 7. |
| 19038680 | Background | Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C; REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008 Dec 2;52(23):1834-1843. doi: 10.1016/j.jacc.2008.08.027. Epub 2008 Nov 7. |
| 28494974 | Background | Zeitler EP, Friedman DJ, Daubert JP, Al-Khatib SM, Solomon SD, Biton Y, McNitt S, Zareba W, Moss AJ, Kutyifa V. Multiple Comorbidities and Response to Cardiac Resynchronization Therapy: MADIT-CRT Long-Term Follow-Up. J Am Coll Cardiol. 2017 May 16;69(19):2369-2379. doi: 10.1016/j.jacc.2017.03.531. |
| 22896584 | Background | Healey JS, Hohnloser SH, Exner DV, Birnie DH, Parkash R, Connolly SJ, Krahn AD, Simpson CS, Thibault B, Basta M, Philippon F, Dorian P, Nair GM, Sivakumaran S, Yetisir E, Wells GA, Tang AS; RAFT Investigators. Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail. 2012 Sep 1;5(5):566-70. doi: 10.1161/CIRCHEARTFAILURE.112.968867. Epub 2012 Aug 14. |
| 27371720 | Background | Daubert C, Behar N, Martins RP, Mabo P, Leclercq C. Avoiding non-responders to cardiac resynchronization therapy: a practical guide. Eur Heart J. 2017 May 14;38(19):1463-1472. doi: 10.1093/eurheartj/ehw270. |
| 29264026 | Background | Okamura H. Up-to-date cardiac resynchronization therapy. J Gen Fam Med. 2017 May 17;18(5):195-199. doi: 10.1002/jgf2.24. eCollection 2017 Oct. |
| 14967109 | Background | Macias A, Gavira JJ, Alegria E, Azcarate PM, Barba J, Garcia-Bolao I. [Effect of the left ventricular pacing site on echocardiographic parameters of ventricular dyssynchrony in patients receiving cardiac resynchronization therapy]. Rev Esp Cardiol. 2004 Feb;57(2):138-45. Spanish. |
| 11748094 | Background | Butter C, Auricchio A, Stellbrink C, Fleck E, Ding J, Yu Y, Huvelle E, Spinelli J; Pacing Therapy for Chronic Heart Failure II Study Group. Effect of resynchronization therapy stimulation site on the systolic function of heart failure patients. Circulation. 2001 Dec 18;104(25):3026-9. doi: 10.1161/hc5001.102229. |
| 26718535 | Background | Umar F, Taylor RJ, Stegemann B, Marshall H, Flannigan S, Lencioni M, De Bono J, Griffith M, Leyva F. Haemodynamic effects of cardiac resynchronization therapy using single-vein, three-pole, multipoint left ventricular pacing in patients with ischaemic cardiomyopathy and a left ventricular free wall scar: the MAESTRO study. Europace. 2016 Aug;18(8):1227-34. doi: 10.1093/europace/euv396. Epub 2015 Dec 30. |
| 26099222 | Background | Bonadei I, Vizzardi E, Gorga E, Carubelli V, Pagnoni M, Sciatti E, Raweh A, Cerini M, Bontempi L, Curnis A, Metra M. Role of the old and new echocardiographic technologies in cardiac resynchronization therapy. Minerva Cardioangiol. 2016 Oct;64(5):572-80. Epub 2015 Jun 23. |
| 31074211 | Background | O'Brien T, Park MS, Youn JC, Chung ES. The Past, Present and Future of Cardiac Resynchronization Therapy. Korean Circ J. 2019 May;49(5):384-399. doi: 10.4070/kcj.2019.0114. |
| 30859220 | Background | Leclercq C, Burri H, Curnis A, Delnoy PP, Rinaldi CA, Sperzel J, Lee K, Calo L, Vicentini A, Concha JF, Thibault B. Cardiac resynchronization therapy non-responder to responder conversion rate in the more response to cardiac resynchronization therapy with MultiPoint Pacing (MORE-CRT MPP) study: results from Phase I. Eur Heart J. 2019 Sep 14;40(35):2979-2987. doi: 10.1093/eurheartj/ehz109. |
| 29454549 | Background | Auricchio A, Heggermont WA. Technology Advances to Improve Response to Cardiac Resynchronization Therapy: What Clinicians Should Know. Rev Esp Cardiol (Engl Ed). 2018 Jun;71(6):477-484. doi: 10.1016/j.rec.2018.01.006. Epub 2018 Feb 14. English, Spanish. |
| 28835138 | Background | Antoniadis AP, Behar JM, Sieniewicz B, Gould J, Niederer S, Rinaldi CA. A comparison of the different features of quadripolar left ventricular pacing leads to deliver cardiac resynchronization therapy. Expert Rev Med Devices. 2017 Sep;14(9):697-706. doi: 10.1080/17434440.2017.1369404. Epub 2017 Aug 23. |
| 23339555 | Background | Tomassoni G, Baker J, Corbisiero R, Love C, Martin D, Niazi I, Sheppard R, Worley S, Beau S, Greer GS, Aryana A, Cao M, Harbert N, Zhang S; Promote(R) Q CRT-D and Quartet(R) Left Ventricular Heart Lead Study Group. Postoperative performance of the Quartet(R) left ventricular heart lead. J Cardiovasc Electrophysiol. 2013 Apr;24(4):449-56. doi: 10.1111/jce.12065. Epub 2013 Jan 22. |
| 25533587 | Background | Crossley GH, Biffi M, Johnson B, Lin A, Gras D, Hussin A, Cuffio A, Collier JL, El-Chami M, Li S, Holloman K, Exner DV. Performance of a novel left ventricular lead with short bipolar spacing for cardiac resynchronization therapy: primary results of the Attain Performa quadripolar left ventricular lead study. Heart Rhythm. 2015 Apr;12(4):751-8. doi: 10.1016/j.hrthm.2014.12.019. Epub 2014 Dec 19. |
| 27434039 | Background | Mittal S, Nair D, Padanilam BJ, Ciuffo A, Gupta N, Gallagher P, Goldner B, Hammill EF, Wold N, Stein K, Burke M. Performance of Anatomically Designed Quadripolar Left Ventricular Leads: Results from the NAVIGATE X4 Clinical Trial. J Cardiovasc Electrophysiol. 2016 Oct;27(10):1199-1205. doi: 10.1111/jce.13044. Epub 2016 Aug 19. |
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided